CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Prothena Presents Pipeline Update Highlighting Two Partnered Phase 3 Programs

By Public Technologies
  • Prothena achieved a $50 million Phase 3 enrollment milestone for coramitug, its partnered treatment for transthyretin amyloid cardiomyopathy.
  • Strategic partnerships have generated $650 million to date, with approximately $2.25 billion in potential downstream milestones across three partnered programs.
  • Phase 3 trials of Parkinson’s treatment prasinezumab and coramitug are ongoing, with completion expected in 2029.
  • Alzheimer’s treatment moponetug is expected to complete its Phase 2 TargetTau-1 trial in the first half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prothena Corporation plc published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk